Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 in HRPC
NCT00286806Phase 2Completed
- Sponsor
- Ascenta Therapeutics
- Start
- Dec 2005
- Primary completion
- Jun 2007
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in prostate cancer (PCa), sponsored by Ascenta Therapeutics. Started Dec 2005; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00286806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286806.